These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 10575321)
21. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031 [TBL] [Abstract][Full Text] [Related]
22. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200 [TBL] [Abstract][Full Text] [Related]
23. Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes. Kümmel S; Eggemann H; Lüftner D; Gebauer N; Bühler H; Schaller G; Schmid P; Kreienberg R; Emons G; Kriner M; Elling D; Blohmer JU; Thomas A Int J Biol Markers; 2007; 22(3):186-93. PubMed ID: 17922461 [TBL] [Abstract][Full Text] [Related]
24. Differences in IGF-axis protein expression and survival among multiethnic breast cancer patients. Hernandez BY; Wilkens LR; Le Marchand L; Horio D; Chong CD; Loo LW Cancer Med; 2015 Mar; 4(3):354-62. PubMed ID: 25619494 [TBL] [Abstract][Full Text] [Related]
25. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cheng I; Penney KL; Stram DO; Le Marchand L; Giorgi E; Haiman CA; Kolonel LN; Pike M; Hirschhorn J; Henderson BE; Freedman ML Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1993-7. PubMed ID: 17035411 [TBL] [Abstract][Full Text] [Related]
26. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753 [TBL] [Abstract][Full Text] [Related]
27. Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Poole EM; Tworoger SS; Hankinson SE; Schernhammer ES; Pollak MN; Baer HJ Am J Epidemiol; 2011 Sep; 174(6):642-51. PubMed ID: 21828371 [TBL] [Abstract][Full Text] [Related]
28. Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status. Barnes BB; Chang-Claude J; Flesch-Janys D; Kinscherf R; Schmidt M; Slanger T; Bonaterra G; Steindorf K Cancer Causes Control; 2009 Dec; 20(10):1985-96. PubMed ID: 19597750 [TBL] [Abstract][Full Text] [Related]
29. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). Patel AV; Cheng I; Canzian F; Le Marchand L; Thun MJ; Berg CD; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Cox DG; Dorronsoro M; Dossus L; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Linseisen J; Lund E; Manjer J; McCarty C; Peeters PH; Pike MC; Pollak M; Riboli E; Stram DO; Tjonneland A; Travis RC; Trichopoulos D; Tumino R; Yeager M; Ziegler RG; Feigelson HS; PLoS One; 2008 Jul; 3(7):e2578. PubMed ID: 18596909 [TBL] [Abstract][Full Text] [Related]
30. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739 [TBL] [Abstract][Full Text] [Related]
31. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Schumacher FR; Cheng I; Freedman ML; Mucci L; Allen NE; Pollak MN; Hayes RB; Stram DO; Canzian F; Henderson BE; Hunter DJ; Virtamo J; Manjer J; Gaziano JM; Kolonel LN; Tjønneland A; Albanes D; Calle EE; Giovannucci E; Crawford ED; Haiman CA; Kraft P; Willett WC; Thun MJ; Le Marchand L; Kaaks R; Feigelson HS; Bueno-de-Mesquita HB; Palli D; Riboli E; Lund E; Amiano P; Andriole G; Dunning AM; Trichopoulos D; Stampfer MJ; Key TJ; Ma J Hum Mol Genet; 2010 Aug; 19(15):3089-101. PubMed ID: 20484221 [TBL] [Abstract][Full Text] [Related]
32. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723 [TBL] [Abstract][Full Text] [Related]
33. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Hankinson SE; Willett WC; Colditz GA; Hunter DJ; Michaud DS; Deroo B; Rosner B; Speizer FE; Pollak M Lancet; 1998 May; 351(9113):1393-6. PubMed ID: 9593409 [TBL] [Abstract][Full Text] [Related]
34. Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity. Kalla Singh S; Tan QW; Brito C; De León M; Garberoglio C; De León D Growth Horm IGF Res; 2010 Apr; 20(2):162-70. PubMed ID: 20089431 [TBL] [Abstract][Full Text] [Related]
35. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Schernhammer ES; Hankinson SE; Hunter DJ; Blouin MJ; Pollak MN Int J Cancer; 2003 Oct; 107(1):60-4. PubMed ID: 12925957 [TBL] [Abstract][Full Text] [Related]
36. Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study. Wu MH; Chou YC; Chou WY; Hsu GC; Chu CH; Yu CP; Yu JC; Sun CA Int J Cancer; 2010 Jan; 126(2):508-14. PubMed ID: 19585556 [TBL] [Abstract][Full Text] [Related]
37. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133 [TBL] [Abstract][Full Text] [Related]
38. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study. Cho EJ; Lee JH; Yoo JJ; Choi WM; Lee MJ; Cho Y; Lee DH; Lee YB; Kwon JH; Yu SJ; Lee JM; Suh KS; Kim K; Kim YJ; Yoon JH; Kim CY; Lee HS Clin Cancer Res; 2013 Aug; 19(15):4218-27. PubMed ID: 23757355 [TBL] [Abstract][Full Text] [Related]
39. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Schernhammer ES; Holly JM; Pollak MN; Hankinson SE Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352 [TBL] [Abstract][Full Text] [Related]
40. Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions. Holdaway IM; Lethaby AE; Mason BH; Singh V; Harman JE; MacCormick M; Civil ID Ann Surg Oncol; 2001; 8(1):25-31. PubMed ID: 11206220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]